ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr4:377856-382256:+ | ACC | EER | T_cells_CD4_naive | 5.2399e-03 | 0.5047 |  |
ENSG00000131127.12,ZNF141 | ACC | EAG | T_cells_CD4_naive | 5.1982e-03 | 0.5051 |  |
chr4:377856-382256:+ | BLCA | EER | Dendritic_cells_resting | 1.8578e-04 | 0.3198 |  |
ENSG00000131127.12,ZNF141 | BLCA | EAG | Dendritic_cells_resting | 2.3085e-04 | 0.3142 |  |
chr4:377856-382256:+ | BRCA | EER | Dendritic_cells_activated | 2.4632e-02 | 0.0892 |  |
ENSG00000131127.12,ZNF141 | BRCA | EAG | Dendritic_cells_activated | 1.1490e-02 | 0.1001 |  |
chr4:377856-382256:+ | CESC | EER | NK_cells_resting | 2.3228e-02 | 0.2490 |  |
ENSG00000131127.12,ZNF141 | CESC | EAG | NK_cells_resting | 2.2246e-02 | 0.2507 |  |
chr4:377856-382256:+ | COAD | EER | T_cells_CD4_memory_activated | 3.5796e-02 | 0.2650 |  |
chr4:377856-382256:+ | ESCA | EER | Neutrophils | 1.0822e-02 | 0.2689 |  |
ENSG00000131127.12,ZNF141 | ESCA | EAG | Mast_cells_resting | 1.1603e-02 | -0.2607 |  |
chr4:377856-382256:+ | HNSC | EER | Eosinophils | 1.2941e-02 | 0.4719 |  |
ENSG00000131127.12,ZNF141 | HNSC | EAG | Eosinophils | 1.2968e-02 | 0.4718 |  |
chr4:377856-382256:+ | KICH | EER | Mast_cells_resting | 4.2623e-02 | 0.2823 |  |
ENSG00000131127.12,ZNF141 | KICH | EAG | Mast_cells_resting | 3.9137e-02 | 0.2870 |  |
chr4:377856-382256:+ | KIRC | EER | Mast_cells_activated | 1.7960e-02 | 0.1640 |  |
ENSG00000131127.12,ZNF141 | KIRC | EAG | T_cells_follicular_helper | 3.8756e-02 | 0.1434 |  |
chr4:377856-382256:+ | KIRP | EER | Neutrophils | 1.0841e-02 | 0.2211 |  |
ENSG00000131127.12,ZNF141 | KIRP | EAG | Neutrophils | 9.1444e-03 | 0.2261 |  |
chr4:377856-382256:+ | LAML | EER | Dendritic_cells_activated | 6.2631e-03 | -0.2960 |  |
ENSG00000131127.12,ZNF141 | LAML | EAG | Monocytes | 8.3723e-03 | 0.2779 |  |
chr4:377856-382256:+ | LGG | EER | Macrophages_M0 | 4.0543e-02 | -0.1204 |  |
ENSG00000131127.12,ZNF141 | LGG | EAG | Macrophages_M0 | 4.8338e-02 | -0.1147 |  |
ENSG00000131127.12,ZNF141 | LUAD | EAG | Neutrophils | 9.2450e-05 | 0.2736 |  |
chr4:377856-382256:+ | LUSC | EER | NK_cells_resting | 9.5562e-03 | 0.2674 |  |
ENSG00000131127.12,ZNF141 | LUSC | EAG | NK_cells_resting | 8.8447e-03 | 0.2701 |  |
chr4:377856-382256:+ | OV | EER | T_cells_CD8 | 3.5199e-05 | 0.2522 |  |
ENSG00000131127.12,ZNF141 | OV | EAG | T_cells_CD8 | 3.8953e-05 | 0.2508 |  |
chr4:377856-382256:+ | PAAD | EER | T_cells_regulatory_(Tregs) | 2.5076e-02 | -0.2915 | .chr4_377856-382256_+.png) |
ENSG00000131127.12,ZNF141 | PAAD | EAG | T_cells_regulatory_(Tregs) | 2.1956e-02 | -0.2978 | .ENSG00000131127.12,ZNF141.png) |
chr4:377856-382256:+ | PCPG | EER | Monocytes | 1.8251e-03 | -0.2762 |  |
ENSG00000131127.12,ZNF141 | PCPG | EAG | Monocytes | 1.5537e-03 | -0.2802 |  |
chr4:377856-382256:+ | STAD | EER | T_cells_CD4_naive | 4.4216e-02 | -0.1489 |  |
chr4:377856-382256:+ | THCA | EER | T_cells_follicular_helper | 3.2462e-02 | 0.1075 |  |
ENSG00000131127.12,ZNF141 | THCA | EAG | T_cells_follicular_helper | 3.2901e-02 | 0.1072 |  |
chr4:377856-382256:+ | THYM | EER | Mast_cells_activated | 3.1942e-02 | -0.2095 |  |
ENSG00000131127.12,ZNF141 | THYM | EAG | Mast_cells_activated | 3.1959e-02 | -0.2095 |  |
chr4:377856-382256:+ | UCEC | EER | T_cells_regulatory_(Tregs) | 3.5040e-02 | 0.2704 | .chr4_377856-382256_+.png) |
ENSG00000131127.12,ZNF141 | UCEC | EAG | NK_cells_activated | 2.9965e-02 | -0.2694 |  |
chr4:377856-382256:+ | UCS | EER | Eosinophils | 6.2667e-03 | 0.4470 |  |
ENSG00000131127.12,ZNF141 | UCS | EAG | Eosinophils | 6.3182e-03 | 0.4466 |  |
chr4:377856-382256:+ | UVM | EER | T_cells_gamma_delta | 1.4203e-04 | 0.7496 |  |
ENSG00000131127.12,ZNF141 | UVM | EAG | T_cells_gamma_delta | 1.4203e-04 | 0.7496 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
chr4:377856-382256:+ | BLCA | GSVA_HALLMARK_P53_PATHWAY | EER | 4.6688e-02 | 0.1735 |  |
chr4:377856-382256:+ | BRCA | GSVA_HALLMARK_GLYCOLYSIS | EER | 1.7273e-04 | 0.1485 |  |
ENSG00000131127.12,ZNF141 | BRCA | GSVA_HALLMARK_GLYCOLYSIS | EAG | 5.1993e-04 | 0.1371 |  |
ENSG00000131127.12,ZNF141 | CESC | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 8.3046e-04 | -0.3600 |  |
chr4:377856-382256:+ | CESC | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 9.1496e-04 | -0.3572 |  |
chr4:377856-382256:+ | COAD | GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS | EER | 1.7087e-02 | 0.2995 |  |
chr4:377856-382256:+ | ESCA | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 3.6009e-02 | 0.2226 |  |
ENSG00000131127.12,ZNF141 | GBM | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EAG | 2.6644e-03 | 0.3003 |  |
chr4:377856-382256:+ | GBM | GSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING | EER | 3.0220e-03 | 0.2966 |  |
ENSG00000131127.12,ZNF141 | HNSC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EAG | 3.9666e-02 | 0.3982 |  |
chr4:377856-382256:+ | HNSC | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 3.9403e-02 | 0.3987 |  |
chr4:377856-382256:+ | KICH | GSVA_HALLMARK_MYC_TARGETS_V1 | EER | 1.0740e-02 | -0.3510 |  |
ENSG00000131127.12,ZNF141 | KICH | GSVA_HALLMARK_MYC_TARGETS_V1 | EAG | 1.1495e-02 | -0.3479 |  |
chr4:377856-382256:+ | KIRC | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 3.6956e-02 | -0.1448 |  |
ENSG00000131127.12,ZNF141 | KIRC | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EAG | 3.5923e-02 | -0.1456 |  |
ENSG00000131127.12,ZNF141 | KIRP | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EAG | 7.1085e-04 | -0.2910 |  |
chr4:377856-382256:+ | KIRP | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 6.5209e-04 | -0.2930 |  |
chr4:377856-382256:+ | LAML | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 4.2311e-03 | 0.3090 |  |
ENSG00000131127.12,ZNF141 | LAML | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 3.6586e-04 | 0.3695 |  |
chr4:377856-382256:+ | LUAD | GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE | EER | 2.9312e-03 | 0.2130 |  |
ENSG00000131127.12,ZNF141 | LUAD | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EAG | 3.9289e-03 | -0.2036 |  |
ENSG00000131127.12,ZNF141 | LUSC | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 4.4196e-02 | 0.2092 |  |
ENSG00000131127.12,ZNF141 | MESO | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 3.4014e-02 | -0.4642 |  |
chr4:377856-382256:+ | MESO | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 3.2680e-02 | -0.4673 |  |
ENSG00000131127.12,ZNF141 | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 2.9740e-03 | 0.1825 |  |
chr4:377856-382256:+ | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 2.4003e-03 | 0.1864 |  |
chr4:377856-382256:+ | PCPG | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 2.0999e-04 | -0.3257 |  |
ENSG00000131127.12,ZNF141 | PCPG | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 2.3215e-04 | -0.3236 |  |
ENSG00000131127.12,ZNF141 | PRAD | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 1.1737e-03 | 0.1755 |  |
chr4:377856-382256:+ | PRAD | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 1.0440e-03 | 0.1773 |  |
ENSG00000131127.12,ZNF141 | READ | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.6799e-02 | 0.4735 |  |
chr4:377856-382256:+ | READ | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.7264e-02 | 0.4718 |  |
chr4:377856-382256:+ | SKCM | GSVA_HALLMARK_ADIPOGENESIS | EER | 1.7206e-02 | -0.1924 |  |
ENSG00000131127.12,ZNF141 | SKCM | GSVA_HALLMARK_ADIPOGENESIS | EAG | 1.7498e-02 | -0.1919 |  |
chr4:377856-382256:+ | STAD | GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE | EER | 1.5716e-02 | 0.1783 |  |
ENSG00000131127.12,ZNF141 | STAD | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 2.1436e-02 | 0.1664 |  |
chr4:377856-382256:+ | TGCT | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EER | 7.1060e-03 | -0.2745 |  |
ENSG00000131127.12,ZNF141 | TGCT | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EAG | 7.1060e-03 | -0.2745 |  |
ENSG00000131127.12,ZNF141 | THCA | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EAG | 1.6406e-02 | -0.1205 |  |
chr4:377856-382256:+ | THCA | GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY | EER | 1.6876e-02 | -0.1200 |  |
chr4:377856-382256:+ | THYM | GSVA_HALLMARK_PROTEIN_SECRETION | EER | 1.8934e-06 | -0.4457 |  |
ENSG00000131127.12,ZNF141 | THYM | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.9002e-06 | -0.4456 |  |
chr4:377856-382256:+ | UCEC | GSVA_HALLMARK_HEME_METABOLISM | EER | 4.8544e-02 | -0.2537 |  |
ENSG00000131127.12,ZNF141 | UCEC | GSVA_HALLMARK_PEROXISOME | EAG | 1.5752e-02 | -0.2984 |  |
ENSG00000131127.12,ZNF141 | UCS | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 1.7946e-02 | 0.3923 |  |
chr4:377856-382256:+ | UCS | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 1.8793e-02 | 0.3897 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
ENSG00000131127.12,ZNF141 | ACC | CI.1040 | EAG | 1.5625e-02 | 0.4448 |  |
chr4:377856-382256:+ | ACC | CI.1040 | EER | 1.5719e-02 | 0.4444 |  |
chr4:377856-382256:+ | BLCA | GW.441756 | EER | 1.7145e-02 | -0.2072 |  |
ENSG00000131127.12,ZNF141 | BLCA | GW.441756 | EAG | 1.9689e-02 | -0.2020 |  |
chr4:377856-382256:+ | BRCA | ATRA | EER | 7.3207e-05 | 0.1570 |  |
ENSG00000131127.12,ZNF141 | BRCA | AICAR | EAG | 1.2544e-04 | 0.1514 |  |
ENSG00000131127.12,ZNF141 | CESC | BMS.509744 | EAG | 6.0422e-08 | -0.5527 |  |
chr4:377856-382256:+ | CESC | BMS.509744 | EER | 5.5068e-08 | -0.5541 |  |
chr4:377856-382256:+ | COAD | Lenalidomide | EER | 1.4127e-02 | 0.3078 |  |
chr4:377856-382256:+ | ESCA | Lenalidomide | EER | 4.8748e-02 | 0.2095 |  |
ENSG00000131127.12,ZNF141 | HNSC | Cytarabine | EAG | 1.3005e-02 | 0.4716 |  |
chr4:377856-382256:+ | HNSC | Cytarabine | EER | 1.2783e-02 | 0.4727 |  |
chr4:377856-382256:+ | KICH | BMS.754807 | EER | 1.1498e-03 | 0.4384 |  |
ENSG00000131127.12,ZNF141 | KICH | BMS.754807 | EAG | 1.1314e-03 | 0.4390 |  |
ENSG00000131127.12,ZNF141 | KIRC | EHT.1864 | EAG | 1.2428e-02 | 0.1731 |  |
chr4:377856-382256:+ | KIRC | EHT.1864 | EER | 1.2793e-02 | 0.1724 |  |
ENSG00000131127.12,ZNF141 | KIRP | AZD6244 | EAG | 4.1216e-03 | -0.2481 |  |
chr4:377856-382256:+ | KIRP | AZD6244 | EER | 4.1263e-03 | -0.2481 |  |
chr4:377856-382256:+ | LAML | AP.24534 | EER | 5.6010e-03 | 0.2998 |  |
ENSG00000131127.12,ZNF141 | LAML | ABT.888 | EAG | 3.1008e-03 | 0.3101 |  |
chr4:377856-382256:+ | LGG | BX.795 | EER | 2.4685e-03 | 0.1771 |  |
ENSG00000131127.12,ZNF141 | LGG | BX.795 | EAG | 1.3505e-03 | 0.1852 |  |
chr4:377856-382256:+ | LIHC | AS601245 | EER | 2.1816e-03 | 0.4599 |  |
ENSG00000131127.12,ZNF141 | LIHC | AS601245 | EAG | 2.1816e-03 | 0.4599 |  |
chr4:377856-382256:+ | LUAD | BMS.509744 | EER | 1.4186e-03 | -0.2281 |  |
ENSG00000131127.12,ZNF141 | LUAD | BMS.708163 | EAG | 5.9403e-04 | -0.2414 |  |
chr4:377856-382256:+ | LUSC | Elesclomol | EER | 4.6625e-02 | 0.2069 |  |
ENSG00000131127.12,ZNF141 | LUSC | Elesclomol | EAG | 3.0376e-02 | 0.2247 |  |
ENSG00000131127.12,ZNF141 | MESO | GSK269962A | EAG | 3.5765e-02 | 0.4603 |  |
chr4:377856-382256:+ | MESO | GSK269962A | EER | 3.4388e-02 | 0.4634 |  |
ENSG00000131127.12,ZNF141 | OV | Cyclopamine | EAG | 7.7028e-05 | -0.2418 |  |
chr4:377856-382256:+ | OV | Cyclopamine | EER | 6.5855e-05 | -0.2440 |  |
chr4:377856-382256:+ | PCPG | BMS.754807 | EER | 3.6799e-04 | -0.3137 |  |
ENSG00000131127.12,ZNF141 | PCPG | BMS.754807 | EAG | 3.5724e-04 | -0.3143 |  |
ENSG00000131127.12,ZNF141 | PRAD | Cisplatin | EAG | 2.3591e-03 | -0.1646 |  |
chr4:377856-382256:+ | PRAD | Cisplatin | EER | 2.1945e-03 | -0.1658 |  |
ENSG00000131127.12,ZNF141 | READ | FH535 | EAG | 1.4036e-03 | -0.6035 |  |
chr4:377856-382256:+ | READ | FH535 | EER | 1.5972e-03 | -0.5979 |  |
ENSG00000131127.12,ZNF141 | SARC | BAY.61.3606 | EAG | 4.2641e-02 | -0.2191 |  |
chr4:377856-382256:+ | SARC | BAY.61.3606 | EER | 4.2789e-02 | -0.2190 |  |
ENSG00000131127.12,ZNF141 | SKCM | CHIR.99021 | EAG | 1.9269e-02 | -0.1890 |  |
chr4:377856-382256:+ | SKCM | CHIR.99021 | EER | 1.9460e-02 | -0.1887 |  |
chr4:377856-382256:+ | STAD | BIRB.0796 | EER | 1.4910e-02 | 0.1797 |  |
ENSG00000131127.12,ZNF141 | STAD | KIN001.135 | EAG | 1.4425e-02 | -0.1768 |  |
chr4:377856-382256:+ | TGCT | Embelin | EER | 1.7476e-02 | 0.2434 |  |
ENSG00000131127.12,ZNF141 | TGCT | Embelin | EAG | 1.7476e-02 | 0.2434 |  |
ENSG00000131127.12,ZNF141 | THCA | Cytarabine | EAG | 5.3008e-04 | -0.1734 |  |
chr4:377856-382256:+ | THCA | Cytarabine | EER | 5.4890e-04 | -0.1729 |  |
chr4:377856-382256:+ | THYM | Embelin | EER | 1.0118e-06 | 0.4561 |  |
ENSG00000131127.12,ZNF141 | THYM | Embelin | EAG | 9.5180e-07 | 0.4571 |  |
ENSG00000131127.12,ZNF141 | UCEC | GW.441756 | EAG | 5.0019e-04 | 0.4197 |  |
chr4:377856-382256:+ | UCEC | Dasatinib | EER | 5.0934e-05 | -0.4946 |  |
ENSG00000131127.12,ZNF141 | UCS | BMS.536924 | EAG | 2.9916e-02 | -0.3623 |  |
chr4:377856-382256:+ | UCS | BMS.536924 | EER | 2.9631e-02 | -0.3628 |  |